Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study
Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2021-10 · 7 (4)
DOI: 10.1177/20552173211048756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal - Experimental, Translational and Clinical, online erschienen am 05.11.2021. Verfasst von Wan-Yu Hsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Multiple Sclerosis Society.
Abstract (Originalsprache)
Background
Sleep disturbances are commonly reported by people with multiple sclerosis (PwMS). However, optimal management of sleep disturbances is uncertain, and objective studies of sleep quality in PwMS are scarce.
Objectives
To determine the effect of exogenous melatonin on sleep quality and sleep disturbances in PwMS.
Methods
Thirty adult PwMS reporting sleep difficulties were recruited in a randomized, controlled, double-blind cross-over study. They took either melatonin or placebo for 2 weeks, and the opposite for the following 2 weeks. During weeks 2 and 4, an actigraph was used to capture mean total sleep time and sleep efficiency. Patient-reported outcomes (PROs) were collected at weeks 0, 2 and 4.
Results
Melatonin use significantly improved mean total sleep time ( p = 0.03), with a trend towards higher sleep efficiency ( p = 0.06). No PROs were significantly different; there was a trend for melatonin use to decrease mean Insomnia Severity Index score ( p = 0.07), improve Pittsburgh Sleep Quality Index sleep quality component ( p = 0.07), and improve NeuroQoL-Fatigue ( p = 0.06). No other PROs showed differences between melatonin and placebo; nor did step count measured by actigraphy (all p > 0.45).
Conclusion
These results provide preliminary evidence that melatonin, a low-cost, over-the-counter supplement, could improve objective measures of sleep quality in PwMS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
- California Pacific Medical Center Research Institute, San Francisco, CA, USA.
- Child & Adolescent Headache Program, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
ORCID-Profile: Wan-Yu Hsu, Riley M Bove
Förderung
- National Multiple Sclerosis Society
Zitieren
APA
Hsu, W. Y., Anderson, A., Rowles, W., Peters, K. E., Li, V., Stone, K. L., Ashbrook, L. H., Gelfand, A. A., & Bove, R. M. (2021). Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(4). https://doi.org/10.1177/20552173211048756
Vancouver
Hsu WY, Anderson A, Rowles W, Peters KE, Li V, Stone KL, et al. Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021;7(4). doi:10.1177/20552173211048756
BibTeX
@article{Hsu2021,
author = {Hsu, Wan-Yu and Anderson, Annika and Rowles, William and Peters, Katherine E and Li, Vicki and Stone, Katie L and Ashbrook, Liza H and Gelfand, Amy A and Bove, Riley M},
title = {Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study},
journal = {Multiple Sclerosis Journal - Experimental, Translational and Clinical},
year = {2021},
volume = {7},
number = {4},
doi = {10.1177/20552173211048756}
}
EUVIMED